Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06526520

Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer

To investigate the levels of Relaxin in different types of endometrial preparation for a frozen embryo transfer cycle. Up to now it is unclear, whether ovulation with a functional corpus luteum (CL) will be present in a natural proliferative phase (NPP) endometrial preparation approach.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

ART Fertiltiy Clinic

Abu Dhabi, Abu Dhabi Emirate, 60202, United Arab Emirates

Location status: Recruiting

Location contact

Barbara Lawrenz

CONTACT

[email protected]

00971526500757

Barbara Lawrenz, PhD

PRINCIPAL_INVESTIGATOR

Jonalyn Edades, MBA

CONTACT

[email protected]

About this study

The last years have seen a distinct shift from fresh (fresh ET) to frozen embryo transfer (FET) cycles. Furthermore it became obvious, that the endometrial preparation approach has a significant impact on the course of the pregnancy and that a HRT endometrial preparation approach is associated with a higher risk for bleeding and miscarriages in early pregnancy and for the development of pregnancy induced hypertension and pre-eclampsia later in pregnancy.

These conditions are attributed to the absence of a CL in the HRT approach. Lately a new endometrial preparation approach is discussed and performed, the so called natural proliferative phase protocol, in which the follicle growth is monitored and when the lining is deemed to have a sufficient thickness and the triple lining pattern, exogeneous progesterone is started to induce secretory transformation before spontaneous ovulation. Despite some studies showing, that exogeneous progesterone administration might induce ovulation, it is not clear whether there will be a CL, producing Relaxin, in the NPP approach.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • regular menstrual cycles

Exclusion criteria

  • abnormal findings of the ovaries (e.g endometriosis)
  • Intake of any hormones within 3 months of study start
  • desire to become pregnant

Treatment and study plan

Exposure to progesterone or HRT medication

Drug

to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol

Primary outcomes

  1. Relaxin measurement

    Time frame: 4 to 6 months

    Measurement of Relaxin in the different types of frozen embryo transfer

Study contacts

Contact information is provided by the study sponsor or research team.

Barbara Lawrenz, M.D. PhD

CONTACT

[email protected]

800 337845489

Jonalyn Edades, MBA

CONTACT

[email protected]

800 337845489

Sponsors and collaborators

Lead sponsor

ART Fertility Clinics LLC

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 29, 2024
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.